ArticleJournal of family medicine and primary care2022
Establishment of the role of myofibroblasts in invasive process of oral squamous cell carcinoma: A pilot study.
Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To establish the role of myofibroblasts in invasive process of oral squamous cell carcinoma (OSCC). Materials and Methods: Four study groups were formed as follows: group 1 consisting of 30 cases of well-differentiated OSCC, group 2 consisting of 30 cases of moderately differentiated OSCC, group 3 consisting of 30 cases of poorly differentiated OSCC, and group 4 consisting of controls. Staining of all of the specimens was done using a-SMA antibody through immunohistochemistry (IHC) procedure. Multiplication product of staining intensity (A) and percentage of a-SMA-stained immuno-positive cells (B) gave a final staining index (FSI). According to FSI, score zero was graded as index zero; score one and two were graded as index low; score three and score were graded as index moderate; and score six, seven, eight and nine were graded as index high. Results: Mean FSI among specimens of groups 1, 2, 3, and 4 was 7.93, 8.47, 8.8, and 0, respectively. Non-significant results were obtained while comparing the mean final staining index among specimens of groups 1, 2 and 3. However; while comparing between groups 1 and 4, groups 2 and 4, and groups 3 and 4, significant results were obtained. While comparing the FSI among overall OSCC group (groups 1, 2 and 3) and controls (group 4), significant results were obtained. Conclusion: Myofibroblasts are an integral component of processes associated with the creation of a permissive environment for cancer invasion process in patients with OSCC. Clinical Significance: Myofibroblasts are associated with the creation of progressive and invasive processes of oral squamous cell carcinoma. Hence, they might be employed as a part of future target for therapeutics in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.